Telomir Pharmaceuticals, Inc. (TELO) stock
Close on Nov 11, 2026Market cap $40.92MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $40.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.29
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$5.48M
- EPS, diluted
- -$0.89
- Book value per share
- $0.06
- Diluted shares
- 69M
Trading
- Previous close
- $0.57
- Open
- $0.59
- Day's range
- $0.57 – $0.71
- Volume
- 322,545
- Average volume (20 days)
- 117,786
- Beta (5 years)
- 1.24
- 52-week range
- $0.55 – $1.58
- RSI (14 days)
- 15.4
- Volatility (1 year)
- 65.9%
- Relative volume
- 3.31×
- WACC
- 11.1%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TELO | S&P 500 | Difference | TELO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.9% | -2.4% | −44.5 pts | ||
| 3 months | -47.3% | -1.2% | −46.2 pts | ||
| Year to date | -55.3% | +12.3% | −67.6 pts | ||
| 1 year | -58.1% | +12.4% | −70.5 pts |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Net income
EPS, diluted
Press releases
Releases Telomir Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Telomir Pharmaceuticals
Pharmaceutical Preparations
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company that develops small-molecule therapeutics targeting fundamental biological drivers of aging and age-related conditions. Its core scientific approach focuses on cellular mechanisms including metal-ion dysregulation, oxidative stress, epigenetic modification, mitochondrial dysfunction, and telomere integrity. The company's lead investigational compound, Telomir-1, is an orally administered molecule designed to modulate intracellular metal balance—specifically iron, copper, zinc, and calcium—through a regulated ion-exchange mechanism. Telomir evaluates this therapeutic candidate across multiple indications, including Wilson’s disease, Type 2 diabetes mellitus, and oncology models such as prostate, breast, and pancreatic cancers.
Company profile, executives and historyTelomir Pharmaceuticals stock: common questions
What is Telomir Pharmaceuticals's stock price?
TELO closed at $0.59 on Nov 11, 2026, up 4.00% on the day. Over the past 52 weeks it traded between $0.55 and $1.58.
What is Telomir Pharmaceuticals's market cap?
Telomir Pharmaceuticals was worth $40.92M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TELO's P/E ratio?
Telomir Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.89), so it has no meaningful P/E ratio.
Does Telomir Pharmaceuticals pay a dividend?
No. Telomir Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has TELO stock performed over the past year?
Including dividends, TELO returned -58.1% over the past year, against +12.4% for the S&P 500.
How many TELO shares are sold short?
1M shares were sold short at the latest FINRA report, 1.52% of the float, or 11.9 days of average trading volume.
Who are Telomir Pharmaceuticals's competitors?
Companies most similar to Telomir Pharmaceuticals by business, industry and size include LGVN, KTTA, MIRA, TCRT, BIOA.
See a number that looks wrong?